Medical research depends on more than science—it depends on trust.
For those considering participation in a clinical study, understanding how research is designed, reviewed, and monitored can help answer an important question: How are participants protected?
The answer lies in decades of ethical standards, oversight, and safeguards designed to ensure that research involving people is conducted responsibly. While medical technologies continue to evolve, the principles guiding ethical research have remained remarkably consistent.
Today in the United States, clinical studies involving human participants are built upon a foundation of ethics, transparency, and informed consent.
Learning From the Past
Modern research protections did not emerge overnight.
Throughout the twentieth century, several highly publicized research abuses revealed the need for stronger safeguards for participants. In response, researchers, regulators, physicians, and ethicists worked together to establish formal ethical frameworks that continue to guide clinical research today.
Two of the most influential are the Declaration of Helsinki, developed by the World Medical Association and widely recognized internationally (2), and the Belmont Report, which serves as a cornerstone of human research protections in the United States (1).
Although written decades ago, these documents continue to shape how studies are designed, reviewed, and conducted.
The Three Principles of the Belmont Report
Published in 1979, the Belmont Report outlines three fundamental ethical principles for research involving human participants (1).
Respect for Persons
Every individual has the right to make informed decisions about participation in research.
Researchers must provide clear information about a study, including its purpose, procedures, potential risks, and alternatives. Participation must be voluntary, and participants may choose not to participate or may withdraw at any time.
Beneficence
Researchers have a responsibility to minimize potential harm and carefully evaluate whether the potential benefits of a study justify its risks.
This principle encourages thoughtful study design, ongoing monitoring, and continuous attention to participant well-being.
Justice
The burdens and benefits of research should be distributed fairly.
This means participant selection should be appropriate and equitable, helping ensure that no group bears an unfair share of research risks or is excluded from potential benefits without good reason.
Together, these principles continue to influence nearly every aspect of clinical research in the United States.
Independent Oversight Through Institutional Review Boards
Ethical principles are only meaningful if they are put into practice.
That is where Institutional Review Boards, or IRBs, play an important role (3).
An IRB is an independent committee that typically includes physicians, scientists, ethicists, and community representatives. Before a clinical study can begin, the IRB reviews the study protocol to evaluate whether participant protections are adequate.
Among other questions, IRBs consider:
- Are potential risks reasonable?
- Is the study designed responsibly?
- Are participants being treated fairly?
- Are appropriate safeguards in place?
Importantly, IRBs operate independently from the research team. They can require modifications to a study, pause enrollment, or stop a study entirely if concerns arise regarding participant safety or ethical conduct.
Why Informed Consent Matters
One of the most visible ways these ethical principles are applied is through informed consent.
Informed consent is more than a signature on a document. It is an ongoing process intended to help participants understand what participation involves before making a decision.
Families considering a study receive information about:
- The purpose of the research
- Study procedures
- Potential risks
- Potential benefits
- Available alternatives
- Participant rights
The goal is transparency. With informed consent, participants receive the information they need to make decisions that align with their own circumstances, values, and preferences.
Moving at the Speed of Safety
Innovation in healthcare requires both scientific progress and public trust.
At Cadence Neuroscience, we believe those tenets go hand in hand. As Cadence CEO Kent Leyde often says, we are committed to “moving at the speed of safety.”
That means respecting the ethical foundations that guide clinical research, communicating transparently, and recognizing the trust families place in the research process.
While technologies continue to evolve, the principles of respect, beneficence, and justice remain constant. They help ensure that research is conducted responsibly, participants are protected, and families can make informed decisions when considering research opportunities.
Sources
- U.S. Department of Health and Human Services. “The Belmont Report.” https://www.hhs.gov/ohrp/regulations-and-policy/belmont-report/index.html
- World Medical Association. “Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects.” https://www.wma.net/policies-post/wma-declaration-of-helsinki/
- Office for Human Research Protections. “Institutional Review Boards (IRBs) and Protection of Human Subjects.” https://www.hhs.gov/ohrp
Cadence Neuroscience is developing investigational medical technologies that have not been approved or cleared by the U.S. Food and Drug Administration (FDA) or other health authorities. Any forward-looking statements reflect current expectations and are subject to risks and uncertainties. Actual results may differ materially. This information is for educational purposes only and does not constitute medical advice or investigational device promotion. Patients should consult qualified healthcare providers regarding diagnosis and treatment options.
Currently, these investigational technologies are only accessible through participation in a clinical trial. To learn more about these investigational technologies and how to access them, talk with your qualified healthcare provider or visit www.clinicaltrials.gov.